SPP-037

• Description:

  SPP-037 is an orally active and selective inhibitor of ST6GAL1 (IC50: 3.59 μM) . SPP-037 exhibits anti-MDA-MB-231 cell migration activity by inhibiting integrin α2,6-sialylation and integrin-FAK-paxillin pathway. SPP-037 has anti-tumor activity in MDA-MB-231 xenograft mouse model. SPP-037 can be used in breast cancer research[1].

• UNSPSC:

  12352211

• Target:

  Endogenous Metabolite; FAK

• Related Pathways:

  Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Smiles:

  [H][C@]12CC[C@@]3([C@H](CC[C@]3([C@@]1(CC[C@@]4(C[C@@H](CC[C@]24C)OC([C@@H](NS(=O)(C5=CC=C(C6=NON=C56)Cl)=O)CC(O)=O)=O)[H])[H])[H])[C@@H](CCCCC(O)=O)C)C

• Molecular Formula:

  C36H50ClN3O9S

• Molecular Weight:

  736.31

• References & Citations:

  [1]Perez SJLP, et al. Harnessing the bishomolithocholic acid scaffold for selective sialyltransferase inhibition: A targeted approach to suppress breast cancer metastasis. Eur J Med Chem. 2025 Aug 5;292:117674.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported